This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Outcome of Board Meeting of Piramal Pharma Limited ( Company ) held on 28th July, 2025 - Financial Results
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than Nifty Smallcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Piramal Pharma reported its Q1 FY26 results on July 28, 2025. On a standalone basis, revenue from operations fell ~8.8% YoY to Rs. 969.88 cr from Rs. 1,063.20 cr, but other income surged to Rs. 180.92 cr (vs Rs. 36.76 cr), lifting total income ~4.6% to Rs. 1,150.80 cr. Standalone net profit jumped ~32.7% YoY to Rs. 113.14 cr (vs Rs. 85.27 cr), with EPS at Rs. 0.85 (vs Rs. 0.64). On a consolidated basis, revenue was nearly flat at Rs. 1,933.71 cr (vs Rs. 1,951.14 cr), and the company reported a net loss of Rs. 81.70 cr, slightly narrower than the Rs. 88.64 cr loss a year ago. A one-time exceptional gain of Rs. 20.74 cr — proceeds from an IBC resolution where step-down subsidiary PCCI recovered dues from a supplier that had quality issues — boosted consolidated results. Auditor Deloitte Haskins & Sells LLP issued an unqualified limited review report on both sets of results.
Standalone shows healthy profitability improvement driven by strong other income (likely treasury/dividend flows), but the weak top-line and the still-negative consolidated bottom line (despite narrowing) signal ongoing pressure in the core pharma business. The exceptional IBC recovery is a positive one-off, but underlying operating performance remains a watchpoint for shareholders.
| Q1 FY26 | Q1 FY25 | Change | |
|---|---|---|---|
| Revenue | ₹1,934 Cr | ₹1,951 Cr | −0.9% |
| Operating profit | −₹176.7 Cr | −₹87.02 Cr | loss widened |
| Profit after tax | −₹81.70 Cr | −₹88.64 Cr | loss narrowed |
| EBITDA margin | 6.6% | 10.5% | −3.9 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.